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Comparative effects of ACE inhibition and angiotensin II re- in the level of inhibition may have implications for the
ceptor blockade in the prevention of renal damage. Angioten- therapeutic effects of AT1RA as compared to ACE I.
sin II (Ang II) regulates a number of genes associated with pro- ACE I reduces only ACE-dependent Ang II produc-
gression of renal disease. The regulation of gene expression by
tion, whereas AT1RA blocks the effect of Ang II fromAng II occurs through specific receptors that are linked to changes
any source at the receptor level. In the presence of ACEin the activity of transcription factors within the nucleus of
target cells. In particular, members of the nuclear factor-B inhibition Ang II may be produced by other proteases,
family of transcription factors are activated, which in turn fuels including chymase and other serine proteases.
at least two autocrine reinforcing loops that amplify Ang II It is known that there are at least two subtypes of AT
and tumor necrosis factor- formation. Angiotensin converting
receptors. Blockade of the AT1 receptors in the presenceenzymes (ACE) inhibitors and angiotensin antagonists (AI-
of Ang II levels may result in the stimulation of subtypeIAs) differ both pharmacokinetically and pharmacodynami-
2 (AT1) receptors. AT1 receptors mediate most of thecally in patients with end-stage renal disease (ESRD). Several
ACE inhibitors (such as captopril, enalapril and lisinopril) are known effects of Ang II such as vasoconstriction, up-
dialyzable, whereas all of the AIIAs studied are not. Dose regulation of aldosterone synthesis and its release, and
titration may be necessary when administering ACE inhibitors renal tubule sodium and water reabsorption.to patients with renal failure (ESRD), but is rarely a consider-
Most of the studies in models of chronic renal diseaseation when AIIAs are used.
indicate that treatment with AT1RA affords renal protec-
tion that is comparable to that observed with ACE inhi-
bition.Intrarenal angiotensin II (Ang II) has important ef-
fects on renal function and urinary sodium excretion
and, via these local actions, on blood pressure regulation. THE BURDEN OF END-STAGE RENAL DISEASE
Angiotensin-converting enzyme inhibitor (ACE I) treat- In the last twenty years, there has been a substantial
ment has been found to be renoprotective in patients with increase in the number of patients treated for end-stage
a variety of chronic renal diseases as well as in diabetic renal disease (ESRD) in the United States [1]. The rea-
patients with nephropathy. sons for this increase are not firmly established. There
Although both ACE I and angiotensin subtype 1 re- are consistent and significant differences in the incidence
ceptor antagonists (AT1RA) are effective in inhibiting rate of ESRD in the various age, sex, and ethnic groups.
renin-angiotensin system (RAS), they differ in their ef- The prevalence and incidence of chronic renal dysfunc-
fects on the components of the system. Inhibition of tion is suspected to be even greater than that of ESRD
ACE results in a decreased conversion of Ang I to Ang II, [2]; however, no nationally representative data are avail-
and a compensatory rise in renin levels due to the loss able on the prevalence of renal dysfunction as estimated
of negative feedback inhibition by juxtaglomerular appa- by serum creatinine levels in the US population.
ratus cells (JGA). In contrast, AT1RA produce elevation A report by Jones et al described the distribution of
in both renin and Ang II because normal feedback inhibi- serum creatinine levels by sex, age, and ethnic group in
tion of JGA cells through stimulation of angiotensin II a representative sample of the US population [3]. Serum
subtype 1 (AT1) receptors is blocked. These differences creatinine level was evaluated in the third National
Health and Nutrition Examination Survey (NHANES
III) in 18,723 participants aged 12 years and older whoKey words: angiotensin converting enzyme inhibition, progressive re-
were examined between 1988 and 1994. The mean serumnal disease, renoprotection, chronic renal disease, diabetic nephrop-
athy. creatinine value was 0.96 mg/dL for women in the United
States and 1.16 mg/dL for men. Overall, among the US 2002 by the International Society of Nephrology
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Table 1. Effect of ACE inhibitors or angiotensin II receptornoninstitutionalized population, 10.9 million people are
antagonists on various parameters associated with renal
estimated to have creatinine values of 1.5 mg/dL or interstitial fibrosis in obstructive nephropathy
greater, 3.0 million have values of 1.7 mg/dL or greater,
AT1 AT2and 0.8 million have serum creatinine levels of 2.0 mg/dL
ACE Receptoror greater.
Parameter Untreated inhibitor antagonist
Interstitial volume    
Monocytes/macrophages    ROLE OF TUBULOINTERSTITIAL DISEASE
Transforming growthIN ESRD
factor-    
Fibroblast proliferation    In 1968 Risdon, Sloper and De Wardener made the
Myofibroblast phenotype    seminal observation that no correlation could be found
Clusterin    
between the degree of histologic glomerular damage and Nuclear factor-B
activation    the decline in renal function, as assessed by glomerular
Values represent a semiquantitative assessment of response during obstructivefiltration rate (GFR) [4]. However, they did find a posi-
nephropathy. A value of () is the maximum response. A value of (0)tive correlation between the histological presence of tu- would indicate no change from normal; however, in each instance there is an
increase in that parameter from normal. (Reproduced with permission from Kidneybular atrophy and a decrease in GFR. Other investiga-
International 52(Suppl 63):S11–S114, 1997.)tors also reported that impaired renal function correlated
best with structural changes in the renal tubulointerstit-
ium [5, 6]. Interstitial fibrosis is a common feature of
long-term ureteral obstruction and other models of renal tion of the AT2 receptor appears to be vasodilatory and
failure. The process of fibrosis, in part, represents an antiproliferative or pro-apoptotic. Most of the pathophysi-
imbalance between deposition of extracellular matrix ologic effects of Ang II, such as vasoconstriction, fibrosis,
(ECM) material and chemoattractant of infiltrating cells. and thrombosis, can be inhibited by specific AT1 receptor
Renal proximal cells and macrophages are a potent blockade.
source of an array of factors such as Ang II, transforming
growth factor-beta (TGF-), interleukin-9 (IL-9), inter-
EFFECT OF PHARMACOLOGIC INTERVENTIONSleukin-6 (IL-6), fibroblast growth factor (FGF), tumor
necrosis factor-alpha (TNF-), and platelet-derived growth Administration of an ACE inhibitor or an angiotensin
factor (PDGF). These growth factors serve as important II receptor (AT1) antagonist, to rats with unilateral ure-
regulators of cell growth and differentiation [7]. Many teral obstruction (UUO), ameliorated the increase in
renal diseases are driven by the intercrine, autocrine, interstitial volume and attenuated the increased expres-
paracrine and endocrine effects of angiotensin II. Ad- sion of TGF-1 in tubular cells, the increased production
ministration of an ACE inhibitor or an angiotensin II of extracellular matrix protein, the activation of NF-B,
(AT1) receptor antagonists to animals with a diversity the proliferation of fibroblasts, and the conversion of their
phenotype to myofibroblasts (Table 1) [9]. A monocyte/of models of renal disease ameliorate the increase in inter-
stitial volume and attenuate the expression of TGF-1 in macrophage infiltrate was present in the obstructed kid-
ney of untreated rats and in the obstructed kidney of ratstubular cells, decrease the production of extracellular ma-
trix protein, activation of nuclear factor-kappa B (NF-B), treated with the AT1 receptor antagonist. By contrast,
this infiltrate was markedly decreased in the obstructedproliferation of fibroblasts, and conversion of their phe-
notype to myofibroblasts. In a model of ureteral obstruc- kidney of rats treated with an ACE inhibitor. This differ-
ence may be due to greater generation of NO related totion a monocyte/macrophage infiltration was present.
Such infiltration was markedly decreased in the obstruc- increased levels of bradykinin during ACE inhibition
[10]. In fact, rats with unilateral obstruction given both antive kidney of rats treated with ACE inhibitor. This effect
may be the result of a greater generation of nitric oxide ACE inhibitor and l-arginine analog N-nitro-l-arginine
methyl ester (L-NAME; an inhibitor of NO formation)(NO) related to increased levels of bradykinin during
ACE inhibition [8]. had a substantial macrophage infiltrate. Administration
of l-arginine in the drinking water significantly bluntedAngiotensin II, the primary effector of the renin-angio-
tensin system (RAS), is produced both systemically and the increases in interstitial volume, monocyte infiltration,
interstitial collagen IV, and -smooth muscle actin ex-locally in various tissues, including the vessel wall and the
heart. This vasoactive substance binds to at least two high- pression [11]. However, in contrast to ACE inhibitors,
arginine administration did not decrease the expressionaffinity cellular receptors, designated the Ang II type 1
(AT1) receptor and the Ang II type 2 (AT2) receptor. of TGF-1 mRNA in the kidney with ureteral ligation.
We also found a tenfold increase in tissue inhibitors ofStimulation of the AT1 receptor is associated with vaso-
constriction and with a hypertrophic or hyperplastic growth metalloproteinase (TIMP-1) mRNA in the obstructed
kidney. Administration of an ACE inhibitor blunted thisresponse in fibroblasts and myocytes, whereas stimula-
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increase by 40% (P  0.001). The addition of L-NAME
to the ACE inhibitor prevented the decrease in TIMP-1
mRNA. A common denominator of the beneficial effects
of ACE inhibition or arginine and the deleterious effects
of L-NAME during ACE inhibition may be a result of
the increased or decreased generation of NO [10, 11].
In these previously mentioned studies, the ACE inhib-
itor was administered before or concomitant with the
onset of ureteral obstruction. We also have examined
the effects of ACE inhibition after three or five days of
established UUO in rats. Delayed administration of an
ACE inhibitor slowed and in several instances halted
the progression of fibrosis in the tubulointerstitium of
the kidney with ureteral ligation.
Pharmacological maneuvers that reduce angiotensin II
(ACE inhibitors) or interfere with its action (AT1 recep-
tor antagonists) blunt NF-B activation and slow the
progression of renal disease. Although AT2 receptor in-
hibition decreases NF-B activation, the effect may be
on NF-B dimers that are different from those affected
through AT1 receptors [12]. Indeed, AT2 receptor inhibi-
tion in rats or AT2 receptor knockout in mice exacerbates Fig. 1. Autocrine reinforcing loops during renal disease progression.
renal fibrosis consequent to ureteral obstruction. Pharma- The regulation of gene expression by angiotensin occurs through specific
receptors that are ultimately linked to changes in the activity of tran-cological maneuvers that reduce the activation of certain
scription factors within the nucleus of target cells. In particular, membersNF-B isotypes may extrinsically blunt angiotensin II- of the nuclear factor-B (NF-B) family of transcription factors are
mediated effects and also slow the progression of renal activated, which in turn fuels at least two autocrine reinforcing loops that
amplify angiotensin II and tumor necrosis factor- (TNF-) formation.disease.
(Reproduced with permission from Seminars in Nephrology 18:622–632,
In summary, Ang II regulates a number of genes asso- 1998.)
ciated with progression of renal disease. The regulation
of gene expression by Ang II occurs through specific
receptors that are ultimately linked to changes in the activ-
appear to be comparable, however, in their antiprotein-ity of transcription factors within the nucleus of target
uric effects. The antagonist losartan is the only drug incells. In particular, members of the NF-B family of
its class capable of lowering uric acid concentrations, atranscription factors are activated, which in turn fuels at
process accomplished by the ability of this compound toleast two autocrine reinforcing loops that amplify angio-
inhibit directly tubule reabsorption of uric acid.tensin II and TNF- formation (Fig 1). This amplification
The change in GFR in a kidney that depends on Ang IIof the angiotensin II and TNF- signals to the same cells
for its function is greater with ACE inhibitors than within an autocrine manner or to adjacent cells in a paracrine
AIIAs. This difference is partly related to the ability ofmanner further amplify NF-B activation within the kid-
ACE inhibitors to increase bradykinin levels (a phenome-ney. This leads to fibroblast proliferation and subsequent
non that is not observed with AIIAs), thereby decreasingdifferentiation into myofibroblasts. Furthermore, tubu-
efferent arteriolar tone. Another contrast between ACElar epithelial cells are stimulated to produce chemoat-
inhibitors and AIIAs is the pharmacokinetic profiles oftractants and adhesion proteins to cause an inflammatory
the drugs in each class. With the exception of fosinoprilresponse, leading to monocyte-macrophage infiltration.
and trandolapril, ACE inhibitors are cleared mainly byThe tubule cells also produce profibrotic cytokines, lead-
the kidney. AIIAs are predominantly cleared by the livering to an overproduction of extracellular matrix proteins
or by the liver and kidney. AIIAs, therefore, do not accu-by all cell types. The net result is fibrosis of the tubulo-
mulate systemically when repetitively doses in patientsinterstitium and progression of renal disease.
with renal failure.
Angiotensin converting enzyme inhibitors and AIIAs
PHARMACOKINETICS OF ACE INHIBITORS differ both pharmacokinetically and pharmacodynamically
AND ANG II ANTAGONISTS in patients with ESRD. ACE inhibitors are associated with
anaphylactoid dialyzer reactions (for example, immedi-Angiotensin converting enzyme inhibitors and angio-
tensin II antagonists (AIIAs) are pharmacokinetically ate hypersensitivity reactions), particularly when poly-
sulfone dialyzers are used. Anaphylactoid dialyzer reac-and pharmacodynamically distinct. These compounds
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tions have not been observed in patients given AIIAs. Two studies published in the New England Journal of
Medicine indicate that losartan [15] or irbesartan [16] con-Residual renal function may change less often with AIIAs,
partly because of the absence of a bradykinin effect on fers significant benefit in patients with type 2 diabetes and
nephropathy. Both losartan and irberstan lead to signifi-the efferent arteriole. There is a difference between ACE
cant improvement in renal outcomes, indicating that theseinhibitors and AIIAs is their respective dialyzability.
Ang II receptor blockers slow the progression of nephrop-Several ACE inhibitors (captopril, enalapril, and lisino-
athy in patients with type 2 diabetes, independently ofpril) are dialyzable, whereas all of the AIIAs studied are
their capacity to lower the systemic blood pressure.not. Dose titration may be necessary when administering
ACE inhibitors to patients with renal failure ESRD, but
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is rarely a consideration when AIIAs are used. In pa- Suite 4300, Washington University at Barnes-Jewish Hospital (North Cam-
pus), 216 South Kingshighway, St. Louis, Missouri 63110-1321, USA.tients with non-dialysis-dependent chronic renal failure,
hyperkalemia may occur less often with AIIAs than with
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